400 related articles for article (PubMed ID: 2521662)
1. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
Anderson PM; Blazar BR; Bach FH; Ochoa AC
J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
[TBL] [Abstract][Full Text] [Related]
2. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
3. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Yun YS; Hargrove ME; Ting CC
Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
[TBL] [Abstract][Full Text] [Related]
5. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
Yoshizawa H; Chang AE; Shu SY
Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
7. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.
Massaro AF; Schoof DD; Rubinstein A; Zuber M; Leonard-Vidal FJ; Eberlein TJ
Cancer Res; 1990 May; 50(9):2587-92. PubMed ID: 2139356
[TBL] [Abstract][Full Text] [Related]
8. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of murine T cell subsets with anti-CD3 antibody. Age-related defects in the expression of early activation molecules.
Ernst DN; Weigle WO; McQuitty DN; Rothermel AL; Hobbs MV
J Immunol; 1989 Mar; 142(5):1413-21. PubMed ID: 2521878
[TBL] [Abstract][Full Text] [Related]
10. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis.
Loeffler CM; Platt JL; Anderson PM; Katsanis E; Ochoa JB; Urba WJ; Longo DL; Leonard AS; Ochoa AC
Cancer Res; 1991 Apr; 51(8):2127-32. PubMed ID: 1826232
[TBL] [Abstract][Full Text] [Related]
12. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells.
Cron RQ; Gajewski TF; Sharrow SO; Fitch FW; Matis LA; Bluestone JA
J Immunol; 1989 Jun; 142(11):3754-62. PubMed ID: 2523934
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice.
Gallinger S; Hoskin DW; Mullen JB; Wong AH; Roder JC
Cancer Res; 1990 Apr; 50(8):2476-80. PubMed ID: 2138507
[TBL] [Abstract][Full Text] [Related]
15. Generation of cytolytic activity with anti-CD3 monoclonal antibodies involves both IL-2-independent and -dependent components.
Stohl W; Tovar Z; Talal N
J Immunol; 1990 May; 144(10):3718-25. PubMed ID: 2139672
[TBL] [Abstract][Full Text] [Related]
16. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
19. A novel surface molecule expressed by long-term cultured T and natural killer cells is involved in cell activation.
Ferrini S; Cantoni C; Ciccone E; Biassoni R; Prigione I; Bottino C; Venzano P; Moretta L
Eur J Immunol; 1991 Sep; 21(9):1981-7. PubMed ID: 1832383
[TBL] [Abstract][Full Text] [Related]
20. Characterization of lymphokines mediating B cell growth and differentiation from monoclonal anti-CD3 antibody-stimulated T cells.
Sherris D; Stohl W; Mayer L
J Immunol; 1989 Apr; 142(7):2343-51. PubMed ID: 2538506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
